Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study

Neuropathologically confirmed and unconfirmed groups

Supplementary Table 1 shows the number of Alzheimer’s dementia cases and cognitively unimpaired controls for each APOE genotype in (a) the Alzheimer’s Disease Genetics Consortium (ADGC’s) clinically characterized and neuropathologically confirmed autopsy group, (b) its clinically characterized but neuropathologically unconfirmed clinical group, and (c) the combined neuropathological and clinical group. The 5007 participants in the neuropathologically confirmed cohort included 4018 AD dementia cases and 989 cognitively unimpaired and neuropathologically unaffected controls. The 23,857 participants in the clinically classified but neuropathologically unconfirmed cohort included 10,430 probable AD dementia cases and 13,426 cognitively unimpaired controls. The 28,864 participants in the combined group included 14,448 cases and…